First AbbVie chopped a PhIII, then they wrote off $4B in book value. Now 178 Stemcentrx workers are getting the ax
AbbVie is steadily chopping away at the people and programs they brought into the company with their big $10 billion Stemcentrx buyout deal.
Back in early January AbbVie wiped $4 billion off the book value of their Stemcentrx assets, a big chunk of the $5.8 billion they spent upfront to get the company and its cancer drug Rova-T. That followed a move to shutter an ongoing trial after researchers spotted a higher risk of death in the drug arm. And now comes news that AbbVie is laying off 178 Stemcentrx workers in South San Francisco, where they’ve been building a big new R&D hub for the company.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.